background

POWER OF PLUS WITH
PURAPLY® AM & PURAPLY® XT

NEW STANDARD OF CARE

Take control before biofilm re-forms. PuraPly AM® and PuraPly® XT provide sustained antimicrobial effectiveness within the product to help prevent biofilm reformation.1-4

  • Native ECM structure provides a scaffold for cellular migration and proliferation (in vitro)1,2,5
  • Provides sustained antimicrobial effectiveness within the product between patient visits4
  • Provides a proactive foundation of care to help prevent biofilm re-formation.3,4
banner-image-background
products

THE POWER OF
PLUS

PuraPly® AM and PuraPly® XT: The ONLY native ECM scaffolds
+ broad-spectrum PHMB antimicrobial1,2

NATIVE,
CROSS-LINKED ECM

BROAD-SPECTRUM
PHMB

Provides a scaffold for cellular migration and proliferation in vitro5

Proactively disrupts
bioburden1,2,6

ecm-icon
phmb-icon

NATIVE, CROSS-LINKED ECM

Provides a scaffold for cellular support migration and proliferation to support granulation tissue formation in vitro5

Extracellular matrix scaffold of PuraPly® AM and PuraPly® XT

Maintains native collagen structure7,8

  • Inhibits a wide range of MMPs and controls excess proteases in vitro3,7,9
  • Ensures strength and compatibility3,7,8

Cross-linked collagen layers3,7,8

  • Strengthens matrix bonds to resist protease degradation10,11
  • Reinforces persistence between patient treatment visits10,11
  • Maximizes surface area for PHMB saturation3,9,12
ECM=extracellular matrix

Broad-Spectrum PHMB

Proactively disrupts bioburden within the product to help prevent biofilm reformation1-3,6

PHMB is onE of the best-investigated antimicrobial substances13

Positively-charged PHMB

  • Demonstrates high tissue compatibility and low cytotoxicity13
  • Will not damage key cells (eg, fibroblasts) involved in wound healing in vitro4
  • Exhibits no known bacterial resistance to date3,6,13

Covers a broad antimicrobial spectrum13

  • Provides sustained antimicrobial effectiveness within the product4
  • Effective against gram-positive and gram-negative bacteria (eg, MRSA, Pseudomonas aeruginosa) and spore-forming bacteria and fungi13
  • Efficacy is not impaired in wound fluid, blood, or tissue13
PHMB=polyhexamethylene biguanide; MRSA=methicillin-resistant Staphylococcus aureus

PERSPECTIVE PAPER SERIES

Specialists, nurses, and researchers across the wound care space provide their
perspectives on the impact of biofilm and the importance of biofilm management.

Gregory Schultz

Gregory Schultz

PhD

A comprehensive biofilm-based management approach: improving standard of care for all wound types.

DOWNLOAD PAPER
John H. Samies

John H. Samies

MD, FSHEA, CWS

Marie L. Gehling

Marie L. Gehling

MSN, NP-C, CWOCN

PuraPly AM for a comprehensive biofilm-based wound management approach.

DOWNLOAD PAPER

CONFIRMATION OF CONTROL

See more product details for PuraPly AM and PuraPly XT, or contact an Organogenesis Tissue Regeneration Specialist to see how PuraPly AM and PuraPly XT can help your patients.

Please refer to the PuraPly AM Instructions for Use and
PuraPly XT Instructions for Use for complete prescribing information.

References:

1. PuraPly Antimicrobial [package insert]. Canton, MA: Organogenesis Inc; 2023. 2. PuraPly XT [package insert]. Canton, MA: Organogenesis Inc; 2023. 4. Davis SC, et al. Int Wound J.2022;19(1):86-99. 5. Data on file. PDR-0008. Organogenesis Inc.6. Gilbert P, et al. J Appl Microbiol. 2005;99(4):703-715.7. Carpenter S, et al. Wounds. 2016;28(6 suppl):S1-S20.8. Data on file. PDR-0007. Organogenesis Inc. 9. Data on file. PDR-0005. Organogenesis Inc. 10. Khor E. Biomaterials.1997;18(2):95-105. 11. Billiar K, et al. J Biomed Mater Res.2001;56(1):101-108. 12. Brett D. Wounds.2008;20(12):347-356. 13. Hübner NO, Kramer A. Skin Pharmacol Physiol. 2010;23(suppl):17-27.